(2S,4R)-1-Tert-Butoxycarbonyl-4-Fluoro-Pyrrolidine-2-Carboxylic Acid

Manufacture of the macrocyclic HCV NS3/4A protease inhibitor grazoprevir (MK-5172) employs (2S,4R)-1-tert-butoxycarbonyl-4-fluoro-pyrrolidine-2-carboxylic acid as the exclusive source of the P2 4-fluoroproline fragment. The fragment is embedded in the final peptide-mimetic scaffold via a sequential deprotection–acylation sequence that demands rigorous stereochemical governance. During the condensation of the liberated (2S,4R)-4-fluoroproline methyl ester with the macrocyclic P1–P3 intermediate, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) hydrochloride and 1-hydroxybenzotriazole (HOBt) are charged at 1.15 eq. and 1.10 eq. relative to the acid, dissolved in anhydrous DMF pre-cooled to 0–5 °C. The amine component concentration is maintained at 0.18–0.22 M to suppress dimerization. Post-coupling, the tertiary-butoxycarbonyl protection remains on the pyrrolidine nitrogen until the final global deprotection with trifluoroacetic acid/triisopropylsilane/water (95:2.5:2.5 v/v/v), carried out in a jacketed glass-lined reactor with anchor agitation at 60–80 rpm and internal temperature −5 °C rising to 23 °C over 90 min. The released intermediate is taken forward as the N-TFAA salt. Acceptance criteria per the US FDA Type II drug master file require chiral purity ≥ 99.8% ee by chiral HPLC (Chiralpak AD-H, 250 × 4.6 mm, hexane/ethanol/TFA 90:10:0.1, 1.0 mL/min, 210 nm), with single unknown impurity ≤ 0.10% and the diastereomeric (2S,4S)-4-fluoro contaminant ≤ 0.15%. The Boc-protected building block itself is supplied under ICH Q7 section 19 for GMP starting materials, typically in 25 kg fiber drums double-lined with LDPE, stored at 2–8 °C and retested every 12 months. In the registered route, 1.25–1.35 t of the acid are consumed per metric ton of grazoprevir anhydrate, with a process mass intensity across the eight downstream stages of 142 kg/kg API.

What limits recovery after Boc reprotection of (2S,4R)-4-fluoroproline crude isolates?

Re-exposure of (2S,4R)-4-fluoroproline free base to di-tert-butyl dicarbonate in aqueous dioxane frequently triggers partial epimerisation at C-2 when solution pH drifts above 9.5 at temperatures exceeding 12 °C. Production campaigns for protease inhibitor candidates that recycle unreacted material via a reprotection loop — often necessary when tight diastereomeric control cannot be achieved in the upstream asymmetric hydrogenation — must operate the Boc installation at 5–8 °C with dropwise addition of sodium carbonate solution at 0.25–0.35 mL/min per 0.5 mol substrate. Tetrahydrofuran as co-solvent at 35% v/v (THF/water) maintains adequate solubility of the zwitterionic intermediate while depressing the equilibrium population of the enolate. In one validated protocol, di-tert-butyl dicarbonate is charged in four equal portions at 45-min intervals under continuous pH-stat control (Metrohm 905 Titrando, pH 8.7 ± 0.2), yielding a crude product with 99.4% de after single extraction into isopropyl acetate. The typical mass recovery from reprotection of off-spec free base is 82–87%; the remainder is lost to 1-(tert-butoxycarbonyl)-4-fluoro-2,3-dihydro-1H-pyrrole-2-carboxylate, a dehydration by-product that forms irreversibly when local sulfuric acid concentration exceeds 0.15 M during preceding salt-break steps.

During manufacture of a clinical-stage factor XIa inhibitor, the protected amino acid is coupled to a 3-(3-chlorophenyl)-1-(2-aminocyclohexyl)urea scaffold under 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) activation. The condensation is sensitive to residual acetate contamination: acetate levels above 650 ppm in the incoming (2S,4R)-Boc-4-fluoroproline acid stagger the acylation rate and generate 4–6% of the epimerised side product because the buffered milieu extends the half-life of the mixed anhydride. Workflow therefore mandates ion-chromatographic release testing (ICS-6000, Dionex IonPac AS11-HC column) with acetate quantified by suppressed conductivity detection and confirmed by δ 1.92 ppm singlet in ¹H NMR at 600 MHz. Coupling is executed in dimethylacetamide maintained at −15 °C with a measured Z-factor of 1.28 for the HATU-HOBt blend, allowing the stoichiometry to be driven to precisely 1.00 eq. without the 2–5% excess conventionally applied to offset hydrate dilution. The ultimate product — a mesylate salt of the elaborated hexapeptide mimetic — carries a process dossier referencing ANSI/ISA-88 batch control; every lot of the Boc-fluoro acid is recorded in the electronic batch record with a unique IR spectral fingerprint (PerkinElmer Spectrum Two, diamond ATR, 4000–450 cm⁻¹, 32 scans).

When a 4-fluoropyrrolidine-2-carboxylic acid scaffold is integrated into a direct-acting antiviral mimicry concept

Non-macrocyclic inhibitors targeting the palm site of influenza virus RNA-dependent RNA polymerase have exploited the constrained pyrrolidine motif to replace the labile proline residue in host-derived peptide substrates. In an exploratory route to a 2-cyano-3-(pyridin-4-yl)acrylamide series, (2S,4R)-Boc-4-fluoro-pyrrolidine-2-carboxylic acid serves as a proline surrogate that sterically clashes with the RNA template entry channel when the 4-fluoro substituent adopts a pseudo-axial orientation. The building block is coupled to a 5-aminopyrazine-2-carboxamide fragment via mixed carbonic anhydride activation using isobutyl chloroformate (1.02 eq.) and N-methylmorpholine (1.30 eq.) in anhydrous tetrahydrofuran at −20 °C, then deprotected with methanolic hydrogen chloride (4 N, 3.0 eq. HCl relative to substrate) to liberate the secondary amine hydrochloride. The non-Boc-free intermediate is immediately redissolved in a vigorously stirred two-phase system of dichloromethane and saturated sodium bicarbonate at 8 °C to forestall fluoride elimination, which becomes kinetically competitive when the medium pH drops below 2.5. The resultant free amine is capped with ethyl cyanoacetate under microwave conditions (Biotage Initiator+, 100 W, 60 °C, 30 min) to furnish the α-cyanovinyl motif. Scale-up to 15 kg input of the Boc-acid required cascade-fed agitation in a 200 L hastelloy reactor with modified retreat-curve impellers to maintain oxygen transfer below 0.05 vvm, given the propensity of the free thiol by-product to form disulfide-linked dimers in aerobic media. Isolated yields of the final acrylamide averaged 78% across 23 batches with a relative standard deviation of 3.2%, as recorded in the tech transfer report filed with MHRA. The elaborated inhibitor displayed a mean IC₅₀ of 18 nM against recombinant H3N2 polymerase in a fluorescence polarization assay (PHERAstar FSX, excitation 540 nm, emission 590 nm), with drop-off in potency to 220 nM when the control (2S)-proline compound was tested, underlining the functional contribution of the 4-fluoro element.

Stereochemical integrity during microwave-assisted solid-phase peptide synthesis misincorporating (2S,4R)-4-fluoroproline

Fmoc solid-phase peptide synthesis of a 26-residue antimicrobial peptidomimetic that replaced every third proline with (2S,4R)-4-fluoroproline exposed an unexpected epimerisation pathway during the Fmoc removal cycle. When the polymer-bound peptide was treated with 20% (v/v) piperidine in DMF for 2 × 5 min at 22 °C, the fluorine-substituted pyrrolidine ring underwent partial (1.5–2.8%) inversion at C-4 to give the (2S,4S) diastereomer, detectable only after resin cleavage and UPLC-QTOF analysis (Waters Vion IMS QTOF, Acquity BEH C18, 100 × 2.1 mm, 1.7 µm, gradient acetonitrile/0.1% formic acid over 8 min). The isomerisation was suppressed by substituting piperidine with 2% (v/v) 1,8-diazabicyclo[5.4.0]undec-7-ene in DMF containing 0.1 M lithium bromide (3 × 3 min), a modification that reduced the undesired diastereomer to ≤ 0.3%. Crude peptide was purified by preparative HPLC (Waters AutoPurification, Xbridge BEH130 Prep C18, 19 × 150 mm, 10 µm) with a linear 18–38% acetonitrile gradient in ammonium bicarbonate buffer (10 mM, pH 8.0. LC-MS of the isolated product confirmed a monoisotopic mass of 3428.62 Da (delta −1.8 ppm). Activity was benchmarked against methicillin-resistant Staphylococcus aureus ATCC 43300 in a broth microdilution assay (CLSI M07-A10), yielding a minimum inhibitory concentration of 4 µg/mL — a 4-fold improvement over the fluorine-deficient analogue. The Boc-protected acid was loaded onto the automated synthesizer (CEM Liberty Blue, 0.10 mmol scale) as a 0.20 M solution in DMF with 5% (v/v) DMSO to enhance solubility; the addition of DMSO necessitated extended coupling times (10 min at 90 °C using DIC/Oxyma Pure activation) and a three-fold wash with DMF to remove residual DMSO, which otherwise attenuated the TFA cleavage efficiency by 11%.

In the production of 18F-labeled trans-4-fluoro-L-proline for positron emission tomography imaging of collagen biosynthesis in pulmonary fibrosis, (2S,4R)-Boc-4-fluoro-pyrrolidine-2-carboxylic acid serves as the non-radioactive reference standard and precursor for the ¹⁹F cold carrier. The Boc group is retained throughout the radiochemical synthesis to prevent chelation of the ¹⁸F-fluoride with the free amine, which would form a tight ion pair and reduce labelling efficiency. Automated synthesis on a GE FASTlab platform requires the precursor — typically the N-Boc-2-carboxy-4-tosylate derivative — to be delivered in anhydrous acetonitrile (1.5 mL) at a concentration of 12 mg/mL, injected into a reactor preconditioned with 2.0 mg of Kryptofix 2.2.2 and 3.5 µL of 0.1 M potassium carbonate. After nucleophilic displacement of the tosylate with ¹⁸F-fluoride at 85 °C for 10 min, the Boc protecting group is removed with 1.0 mL of 5 M trifluoroacetic acid at 23 °C for 3 min, then neutralised with 2.5 mL of 2 M sodium citrate. The crude hydrolysate is purified by semi-preparative radio-HPLC (Phenomenex Luna C18(2), 250 × 10 mm, 5 µm, isocratic 0.1% phosphoric acid at 4.0 mL/min), with the product fraction collected between 10.5 min and 13.0 min. Radiochemical purity as determined by radio-TLC and radio-HPLC must exceed 95%, and the molar activity at end of synthesis averaged 42 GBq/µmol across 47 consecutive runs. The Boc-acid reference standard is stored in 2 mg aliquots under argon at −20 °C to prevent gradual decarboxylation induced by condenser defrost cycles; batch re-qualification after 24 months indicated 0.4% total degradation, primarily to 4-fluoro-pyrrolidine, a degradant that co-elutes with the radiochemical impurity at RRT 0.82.

When (2S,4R)-Boc-4-fluoro-pyrrolidine-2-carboxylic acid is stockpiled as a universal proline analog for fragment-based drug discovery, parallel microscale amidation against 384 structurally diverse amines under acoustic dispensing conditions reveals a reproducible reactivity cliff at high dilution. The acid is dissolved in DMSO-d₆ with 0.1% v/v TFA-d as an internal lock standard, and dispensed in 50 nL droplets (Labcyte Echo 655T) into 100 nL dry film of HATU and DIPEA in dimethylacetamide. Under these conditions, the amidation efficiency spans 19–93% depending on the steric demand of the amine; primary aliphatic amines react to completion within 15 min at 28 °C, whereas N-methylanilines require 60 min and a second addition of HATU (1.2 eq.) to surpass 50% conversion. The library requires no Boc removal before biochemical screening when profiling against serine hydrolases, because the carbamate moiety forms a reversible tetrahedral intermediate with the active-site serine, giving an apparent inhibition constant that can be directly correlated to the free amine after mathematical correction for the tert-butyl effect. Data from 11,200 compounds generated in this fashion populate a corporate screening collection where the hit rate for selective protein–protein interaction disruptors improved from 0.18% to 0.47% when the 4-fluoroproline scaffold replaced proline in the master plate design, according to an internal technical report validated by an independent statistical review (K. Pearson χ² = 8.74, p < 0.005).